Increasing Rates of Perioperative Chemotherapy are Associated With Improved Survival in Men With Urothelial Bladder Cancer With Prostatic Stromal Invasion
- 1 February 2020
- journal article
- research article
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 18 (1) , 35-44.e1
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Comparison of SEER Treatment Data With Medicare ClaimsMedical Care, 2016
- Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder CancerJournal of Clinical Oncology, 2016
- The performance of inverse probability of treatment weighting and full matching on the propensity score in the presence of model misspecification when estimating the effect of treatment on survival outcomesStatistical Methods in Medical Research, 2015
- Trends in the Utilization of Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Results From the National Cancer DatabaseUrology, 2014
- Incidence, survival and mortality rates of stage-specific bladder cancer in United States: A trend analysisCancer Epidemiology, 2013
- International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 TrialJournal of Clinical Oncology, 2011
- Neoadjuvant Chemotherapy in Invasive Bladder Cancer: Update of a Systematic Review and Meta-Analysis of Individual Patient DataEuropean Urology, 2005
- Neoadjuvant Cisplatinum Based Combination Chemotherapy in Patients with Invasive Bladder Cancer: A Combined Analysis of Two Nordic StudiesEuropean Urology, 2004
- Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder CancerNew England Journal of Medicine, 2003
- Neoadjuvant Chemotherapy with Cisplatin and Methotrexate in Patients with Muscle-Invasive Bladder TumoursActa Oncologica, 2002